Royce & Associates LP Has $9.11 Million Position in Progenics Pharmaceuticals, Inc. (PGNX)

Royce & Associates LP lifted its position in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 23.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,453,456 shares of the biotechnology company’s stock after purchasing an additional 276,200 shares during the quarter. Royce & Associates LP owned about 1.72% of Progenics Pharmaceuticals worth $9,113,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Progenics Pharmaceuticals during the second quarter worth about $125,000. NumerixS Investment Technologies Inc lifted its position in shares of Progenics Pharmaceuticals by 163.3% during the second quarter. NumerixS Investment Technologies Inc now owns 15,800 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 9,800 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Progenics Pharmaceuticals during the second quarter worth about $281,000. Virtu Financial LLC acquired a new stake in shares of Progenics Pharmaceuticals during the third quarter worth about $327,000. Finally, Credit Suisse AG lifted its position in shares of Progenics Pharmaceuticals by 22.2% during the third quarter. Credit Suisse AG now owns 78,520 shares of the biotechnology company’s stock worth $492,000 after purchasing an additional 14,253 shares in the last quarter. 92.09% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently issued reports on PGNX. Credit Suisse Group began coverage on shares of Progenics Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $6.50 price target on the stock. BidaskClub cut shares of Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday. ValuEngine cut shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 25th. Finally, Needham & Company LLC cut shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and reduced their price target for the stock from $16.00 to $12.00 in a research report on Thursday, September 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $10.65.

Shares of NASDAQ:PGNX opened at $4.56 on Friday. Progenics Pharmaceuticals, Inc. has a fifty-two week low of $4.47 and a fifty-two week high of $9.42. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.33.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.09. The firm had revenue of $5.32 million for the quarter, compared to analysts’ expectations of $4.14 million. Progenics Pharmaceuticals had a negative net margin of 341.78% and a negative return on equity of 66.86%. On average, analysts predict that Progenics Pharmaceuticals, Inc. will post -0.76 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/12/08/royce-associates-lp-has-9-11-million-position-in-progenics-pharmaceuticals-inc-pgnx.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply